Amara Maple
BOLOGNA, ITALY – A leading scientist, Dr. Daniele Mandrioli, has been removed from his position as chief scientist at the Ramazzini Institute Cesare Maltoni Cancer Research Center, sparking widespread concern among the international scientific community regarding potential undue influence from the chemical industry. Dr. Mandrioli was at the helm of a groundbreaking, independently funded study investigating the safety of glyphosate, the active ingredient in the widely used herbicide Roundup. The allegations of industry pressure come to light through the investigative reporting of Carey Gillam, a veteran journalist renowned for her deep dives into corporate accountability and the agrochemical sector.
The Ramazzini Institute and the Global Glyphosate Study
The Ramazzini Institute, located near Bologna, Italy, has a long and distinguished history dating back to 1971, serving as a critical toxicology research center. Over decades, the institute has meticulously studied more than 200 substances, with its findings frequently informing regulatory bodies in Europe and the United States. Its work is highly regarded for its independence and rigor, particularly its long-term animal studies designed to assess the carcinogenic and toxic effects of various compounds.
In recent years, recognizing the escalating global usage of glyphosate and the ongoing public health debate surrounding its safety, the Ramazzini Institute launched an ambitious initiative: the "Global Glyphosate Study." Unlike many industry-sponsored studies, this multi-pronged research effort was notably funded through "worldwide crowdfunding," deliberately sidestepping financial ties to chemical manufacturers. The study’s primary objective was to explore the effects of glyphosate herbicides when exposed at "current real-world levels" across several toxicological endpoints, including carcinogenicity, endocrine disruption, and reproductive impacts.
Dr. Mandrioli, a long-standing and respected figure at the Institute, was the director overseeing this comprehensive investigation. His leadership was marked by a commitment to transparency and a willingness to openly discuss preliminary findings, which, according to reports, had begun to raise significant concerns about glyphosate’s safety profile.
Preliminary Findings and Industry Backlash
Last summer, the Ramazzini Institute issued an interim report from the Global Glyphosate Study. This report reportedly strengthened existing evidence suggesting that glyphosate herbicides, even at doses considered safe by some regulators, could cause tumors in animals and potentially contribute to cancers in humans. This was not the first time the Institute had published findings critical of glyphosate; earlier studies had indicated potential endocrine and reproductive impacts.
Such findings, when disseminated by independent research bodies, have historically been met with fierce opposition from the agrochemical industry, particularly from companies like Bayer (which acquired Monsanto, the original developer of Roundup, in 2018). Dr. Mandrioli, given his outspoken nature regarding the study’s results, became a target of this industry scrutiny. Carey Gillam reported that Mandrioli had been "under intense pressure" following the release of these preliminary findings.
The culmination of this pressure, as reported by Gillam, was the directive for Dr. Mandrioli to leave the institution. He was informed of his dismissal, effective the end of December 2025, though he concluded his remaining work and departed at the end of January 2026.
Allegations of Undue Influence and Scientific Outrage
The sudden dismissal of Dr. Mandrioli has ignited a firestorm within the scientific community. Ramazzini Institute President Loretta Masotti has publicly asserted that the termination was not a result of pressure from the chemical industry. However, this assertion has been met with skepticism and outright outrage from many scientists associated with the Institute.
Dr. Philip Landrigan, a highly respected public health physician and the head of the International Scientific Advisory Committee of the Ramazzini Institute, penned a sharply worded letter to President Masotti on January 21, 2026. In his letter, Dr. Landrigan unequivocally stated: "Dr. Mandrioli has been subjected to vicious attacks by the chemical industry because the findings of the Institute’s independent research have cost these companies money and hurt their bottom line."
The lack of consultation with the advisory board and other key academics involved with the research center before Mandrioli’s dismissal further fueled concerns. Scientists have reportedly sent letters attempting to save his position, arguing that such actions directly threaten the independence and integrity of both the research center and the Institute as a whole. This incident underscores a broader fear within the scientific community: that independent research challenging powerful corporate interests can lead to professional repercussions for the researchers involved.
Carey Gillam: A Voice for Accountability
The story of Dr. Mandrioli’s ouster was first brought to light by Carey Gillam, an investigative journalist with a long track record of exposing the hidden aspects of the agrochemical industry. Gillam is the author of two seminal books on the subject: "Whitewash: The Story of a Weed Killer, Cancer, and the Corruption of Science" (Island Press, 2018) and "The Monsanto Papers: Deadly Secrets, Corporate Corruption, and One Man’s Search for Justice" (Island Press, 2021). Her work has consistently highlighted the alleged tactics employed by powerful corporations to suppress inconvenient scientific findings and influence public perception.
Currently, Gillam leads "The New Lede," a journalism initiative operating under the umbrella of the Environmental Working Group (EWG). Her interview with Corporate Crime Reporter last week provided crucial details and context surrounding Dr. Mandrioli’s dismissal and the wider implications for scientific integrity.
Gillam’s reporting draws parallels between Dr. Mandrioli’s situation and previous instances where scientists investigating the health effects of glyphosate have faced significant pushback. A prominent example she cites is the experience of scientists at the International Agency for Research on Cancer (IARC), a specialized cancer agency of the World Health Organization (WHO). In March 2015, IARC classified glyphosate as "probably carcinogenic to humans." This classification triggered an unprecedented wave of attacks from the chemical industry, which accused IARC scientists of publishing "junk science," manipulating results, and intentionally misleading the public.
These attacks extended to personal assaults on the scientists’ integrity and credibility, demands for subpoenas of private emails, pressure on the WHO to retract the findings, calls for a Congressional investigation into IARC, and efforts to strip the agency of its funding. A House committee did indeed launch an investigation, with Republican members leveling various insults at IARC, leaving a "tarnish" on the agency due to its glyphosate work. Similar attacks have been launched against independent scientists at institutions like the University of Washington, illustrating a pattern of industry response to unfavorable research.
The Landscape of Glyphosate Litigation
The IARC’s 2015 classification of glyphosate as a probable human carcinogen was a pivotal moment, triggering an "avalanche of litigation" across the United States. Thousands of individuals diagnosed with non-Hodgkin lymphoma, who attributed their disease to exposure to glyphosate-based herbicides like Roundup, filed lawsuits against Monsanto.
The legal landscape shifted dramatically in 2018 when Bayer AG acquired Monsanto for approximately $63 billion, just as the first major trial against Roundup was commencing. This acquisition saddled Bayer with immense legal liabilities. To date, Bayer has reportedly paid out over $11 billion in settlements and jury verdicts, attempting to stem the tide of litigation.
The scale of the litigation is staggering. Close to 200,000 lawsuits were initially filed in the United States. While many have been settled, approximately 50,000 to 60,000 cases remain unresolved, according to Bayer’s own estimates. Settlements have been confidential and highly variable, ranging from tens of thousands to a few million dollars, with many plaintiffs receiving modest sums after legal fees.
Dozens of cases have gone to jury verdict, with both plaintiffs and Bayer securing wins. Several high-profile cases have resulted in substantial jury awards, including an initial verdict of $289 million in 2018, followed by a $2 billion verdict, and another for $80 million. These landmark verdicts underscored the potential for significant liability, even as Bayer continued to vigorously defend the safety of glyphosate.
Bayer’s Legal and Legislative Strategies
To mitigate its ongoing financial exposure and halt future litigation, Bayer has pursued multiple strategies. A key legal tactic involves an appeal to the U.S. Supreme Court in the Roundup litigation. Bayer argues that state-based "failure to warn" claims should be pre-empted by federal law. Their contention is that since the Environmental Protection Agency (EPA) is the chief regulator of pesticides and does not mandate a cancer warning on glyphosate labels, states should not be able to allow lawsuits against Bayer for failing to warn of a cancer risk. This crucial question is scheduled to be heard by the Supreme Court this spring, with a decision anticipated by June. Bayer has expressed strong optimism to its investors that a favorable ruling could significantly block future litigation and potentially end existing cases.
Beyond the courts, Bayer has engaged in aggressive legislative lobbying. The company is actively working to embed this pre-emption argument into federal and state laws, effectively creating an "immunity shield" for pesticide manufacturers. This involves lobbying lawmakers to enact provisions stating that the EPA’s authority on pesticide labeling is supreme, thereby disallowing state-level failure-to-warn claims. Such laws have already been passed in two states, and similar efforts are underway in others. Legal experts note that "failure to warn" is often the "linchpin" of these lawsuits; without it, other claims like design defect or negligence may become significantly weaker or "fall apart."
To bolster its legislative efforts, Bayer has formed the "Modern Ag Alliance," a coalition comprising dozens of agricultural groups across the country. This alliance argues that without such protective laws, glyphosate’s market viability could be jeopardized due to the prohibitive costs of litigation, potentially impacting agricultural practices and the broader economy. They often frame plaintiff attorneys as "exploiting people who are suffering from cancer by bringing claims that have no scientific validity," arguing that companies require protection from "predatory law firms." These arguments are gaining traction on Capitol Hill, with expectations that some form of this language may appear in the upcoming federal farm bill.
Advocacy and the "Make America Healthy Again" Movement
Countering Bayer’s lobbying efforts is a burgeoning grassroots movement, "Make America Healthy Again" (MAHA). This movement played a crucial role in successfully stripping an "immunity provision" from a recent U.S. Congressional appropriations bill. MAHA activists, many of whom have expressed deep frustration with what they perceive as a lack of substantive action from government agencies, including the Trump administration and even prominent figures like Bobby Kennedy, their leader, are advocating for more rigorous regulation of pesticides and environmental chemicals.
Their frustration intensified when an initial draft report from the Department of Health and Human Services, compiled under Kennedy’s leadership, named glyphosate and atrazine as dangerous chemicals requiring stricter regulation. However, following intensive lobbying by agrichemical companies on Capitol Hill, the final report released last fall made no mention of these pesticides. This perceived capitulation fueled MAHA’s resolve.
MAHA has since launched petitions, including one calling for the ouster of EPA chief Lee Zeldin, whom they accuse of prioritizing corporate interests over public health. While Zeldin has reportedly attempted to appease MAHA, activists argue that these efforts have not translated into meaningful policy changes to rein in pesticide use or strengthen regulations. The ongoing struggle between industry lobbying and public health advocacy highlights the complex and often contentious battle over chemical regulation in the United States.
Implications for Scientific Independence and Public Health
The unfolding events surrounding Dr. Mandrioli’s dismissal and the broader context of glyphosate litigation and legislative maneuvering carry significant implications for scientific independence and public health worldwide. The pressure exerted on researchers and institutions that produce findings unfavorable to powerful industries raises serious questions about the integrity of scientific inquiry and the ability of independent science to inform public policy without fear of reprisal.
If researchers are systematically targeted or removed for their findings, it could create a chilling effect, discouraging critical investigations into potentially harmful substances. This, in turn, could compromise the public’s right to unbiased information about environmental health risks and hinder the development of effective regulatory safeguards.
The outcome of Bayer’s Supreme Court appeal will be a landmark decision, potentially reshaping the landscape of product liability law for pesticides and other regulated products. A ruling in Bayer’s favor could severely limit the ability of individuals harmed by such products to seek redress, effectively granting federal agencies the sole authority to determine warnings, even if those warnings are deemed inadequate by scientific bodies or the public.
As the debate continues and legal and legislative battles unfold, the spotlight remains firmly on the delicate balance between corporate interests, scientific integrity, and the fundamental right to public health. The case of Dr. Mandrioli at the Ramazzini Institute serves as a stark reminder of the ongoing challenges in ensuring that scientific truth can prevail against powerful economic forces.
Pevita Pearce
Eva Lovia
Nila Kartika Wati
Jia Lissa
Ana Megawati